GT Medical Technologies Welcomes Second GammaTile® Center of Excellence Designation

Recognizing leaders in patient care and education for patients with operable brain tumors

TEMPE, Ariz., April 30, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced AdventHealth Orlando as the second GammaTile^® Center of Excellence designation.

The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual operable brain tumor case minimums, and ongoing education requirements.  

GammaTile is thrilled to announce AdventHealth Orlando as the second Center of Excellence designation. The following physicians are now recognized with this achievement:

• Imran Mohiuddin, MD, PhD, Radiation Oncologist, Director of CNS Radiosurgery, Co-Director of Gamma Knife^®
• Christopher Baker, MD, Neurosurgeon
• Michael Bellew, MD, Neurosurgeon
• Melvin Field, MD, Neurosurgeon
• Ravi Gandhi, MD, Neurosurgeon
• David Rosen, MD, Neurosurgeon

"GT Medical Technologies is pleased to designate these exceptional institutions and physicians for their unwavering commitment to improving patient outcomes and quality of life," said Per Langoe, Chief Executive Officer at GT Medical Technologies. "Together, we will continue to elevate the standard of care for patients and pave the way for the future of brain tumor treatment." 

GammaTile is an innovative form of radiation therapy placed at the time of tumor surgical removal, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.¹

"Achieving recognition as a GammaTile Center of Excellence underscores our unwavering commitment to advancing patient standard of care," said Dr. Imran Mohiuddin. "At AdventHealth Orlando, we take pride in offering our patients innovative treatments like GammaTile."

About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.

Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X. 

Media Contact
Dawn Fallon
New Dawn Communications LLC
[email protected]
732-771-7808 

References

1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).

View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-medical-technologies-welcomes-second-gammatile-center-of-excellence-designation-302442074.html

SOURCE GT Medical Technologies